Mp-MRI in the Diagnosis of Liver Fibrosis After Liver Transplantation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05292885

Enrollment

Registered

2022-03-23

Start date

2022-03-18

Completion date

2022-12-01

Last updated

2022-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis After Liver Transplantation, Multiparameter Magnetic Resonance Imaging

Brief summary

It is an open label observation clinical trial, all participants are liver transplant patients. The investigators deem to make a better criteria for assessing liver fibrosis after liver transplantation. The point of the clinical trial is to evaluate the efficacy of multiparameter MRI in the diagnosis of liver fibrosis after liver transplantation.

Detailed description

We collected patients aged 18 to 85 who had undergone liver transplantation. At the same time, all patients underwent liver biopsy or ultrasonic transient elastography after MRI. People who were allergic to gadolinium contrast agent, serious cardiopulmonary disease and contraindications to MRI were excluded.

Interventions

DIAGNOSTIC_TESTGadopentetate Dimeglumine Injection

Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Inclusion criteria

* Subjects aged 18 -85 years * Patients after liver transplantation * Patients who are going to undergo liver biopsy or ultrasonic transient elastography * Patients voluntarily joined the study and signed informed consent

Exclusion criteria

* Patients with tumor * Patients who are allergic to gadolinium contrast agent * Patients with contraindications to magnetic resonance imaging * Patients with severe heart and lung diseases * Patients who are not suitable for this study according to the researcher's judgment.

Design outcomes

Primary

Measure	Time frame	Description
Mp-MRI in the Diagnosis of Liver Fibrosis After Liver Transplantation	03.18.2022 to12.01.2022	Mp-MRI as a PET-CT biomarker to Liver Fibrosis after Liver Transplantation

Countries

China

Contacts

Primary ContactGuangjie Yang, PhD

ygj_2815@qq.com+86 053282913399

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026